杭州安旭生物科技股份有限公司 2025年第三季度报告

Core Points - The company assures that the quarterly report is true, accurate, and complete, with no false records or significant omissions [2][3] - The financial statements for the third quarter are unaudited [3][5] - The company has not identified any non-recurring gains or losses during the reporting period [3][4] Financial Data Summary - The financial data is presented in RMB, with the reporting period defined as the three months from the beginning to the end of the quarter [3] - The company has not reported any changes in major accounting data or financial indicators [4][5] - The company has not executed any new accounting standards or interpretations affecting the financial statements for the current year [6] Shareholder Information - There are no changes reported in the top ten shareholders or any significant shareholder activities during the reporting period [4] Other Important Information - The company has not identified any additional important information regarding its operational performance during the reporting period [5] - The financial statements include the consolidated balance sheet and cash flow statement for the first nine months of 2025, both of which are unaudited [5][6]